- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- June 2024
- 200 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1899EUR$2,000USD£1,602GBP
- Report
- January 2022
- 60 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- November 2023
- 190 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- April 2023
- 120 Pages
Global
From €4509EUR$4,750USD£3,804GBP
Pediatric Neuroblastoma Treatment is a type of oncology drug used to treat a type of cancer that affects children. It is a type of cancer that develops from immature nerve cells found in various parts of the body. Neuroblastoma is the most common cancer in infants and the most common solid tumor in children. Treatment for pediatric neuroblastoma typically involves a combination of surgery, chemotherapy, radiation therapy, and immunotherapy. Surgery is used to remove the tumor, while chemotherapy and radiation therapy are used to kill any remaining cancer cells. Immunotherapy is used to help the body's immune system fight the cancer.
Some companies in the Pediatric Neuroblastoma Treatment market include Novartis, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more